2025年氟替美维吸入粉雾剂(Trelegy Ellipta)最新价格是多少钱一盒？

The latest price of flutimavir inhalation powder (TrelegyEllipta) in 2025 may vary due to different medical insurance reimbursement ratios, and the actual price needs to prevail.

What is the latest price of a box of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta) in 2025?

It has been included in China’s National Medical Insurance Directory, which greatly reduces the financial burden on patients. The actual prices of drugs are not uniform and will vary.

The proportion of medical insurance reimbursement in various places may vary due to regional policies and other factors, and the procurement and pricing of different levels of hospitals and pharmacies may also fluctuate slightly.

If you want to obtain the most accurate and up-to-date prices, it is recommended that patients consult the pharmacies of local designated hospitals or inquire through regular pharmacies.

Contraindications of flutimavir inhalation powder (Trelegy Ellipta)

1. Treatment of acute attacks

It should not be used as primary treatment for status asthmaticus or other acute COPD or asthma attacks that require emergency rescue. This medicine is a maintenance treatment and is not intended for rapid relief of acute bronchospasm.

2. Severe allergic reaction

It is contraindicated for patients with a history of severe allergy to any active ingredient or excipient of flutimavir inhalation powder.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Precautions when using Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. Be alert to the risk of infection

(1) Oral candidiasis: Long-term use may increase the risk of fungal infection in the mouth and throat. Mouthwash is an effective preventive measure.

(2) Pneumonia: Patients with chronic obstructive pulmonary disease have a higher risk of pneumonia themselves, and the use of drugs containing ICS may further increase this risk. If you have persistent fever, chills, worsening cough, change in sputum color, or worsening difficulty breathing, you should seek medical attention immediately.

(3) Other infections: It may worsen existing tuberculosis, fungal, bacterial, viral and parasitic infections.

2. Systemic effects and adrenal function

Long-term high-dose inhalation or combined use with strong CYP3A4 inhibitors (such as ketoconazole) may lead to systemic corticosteroid effects, such as Cushing's syndrome and adrenal suppression.

When switching from oral corticosteroids to this product, you need to slowly reduce the dose of oral medication under the guidance of a doctor, and closely monitor for signs of adrenal insufficiency (such as abnormal tiredness, weakness, nausea, hypotension).

3. Cardiovascular and metabolic effects

The LABA component (vilanterol) may cause increased heart rate, increased blood pressure or arrhythmia; patients with cardiovascular disease should use it with caution; it may cause a decrease in potassium and an increase in blood sugar, and patients with diabetes need to pay attention to monitoring.

4. Effects on other organs

(1) Eye problems: Long-term use of ICS may increase the risk of glaucoma and cataracts. If symptoms such as eye pain, blurred vision, or visual halo effect occur, seek medical attention immediately.

(2) Urinary system: The anticholinergic component (umeclidinium bromide) may aggravate urinary difficulty in patients with prostatic hyperplasia. If symptoms of urinary retention occur, the medication should be discontinued and medical attention should be sought.

(3) Bone health: Long-term use of ICS may lead to a decrease in bone density, and patients at risk of osteoporosis should be monitored regularly.